Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Genmab reported worldwide net sales of DARZALEX (daratumumab) of USD 4,207 million for the second quarter of 2026, as reported by license partner Johnson & Johnson. Net trade sales in the U.S. reached USD 2,435 million, while sales in the rest of the world totaled USD 1,772 million.
Key figures
- Darzalex q2 2026 net sales usd
- 4207000000
- Darzalex q2 2026 net sales us usd
- 2435000000
- Darzalex q2 2026 net sales row usd
- 1772000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.